Amgen Inc.

Knopp Biosciences, LLC

Biohaven Therapeutics Ltd.

Array Biopharma Inc.

Scott S Harried

David A Mareska

George T Topalov

James S Hale

Lynn Resnick

Charles A Flentge

Justin K Belardi

Stephen A Hitchcock

Thomas T Nguyen

Wenge Zhong

Holger Monenschein

Patricia Lopez

Qiufen May Xue

Matthew R Kaller

Ted Charles Judd

James A Brown

Michael D Croghan

Vinod Francis Patel

Matthew M Weiss

Bryant Yang

Charles Kreiman

Yuan Cheng

Russell Graceffa

Daniel B Horne

Wenyuan Qian

Thomas Nixey

Craig E Masse

Jian Jeffrey Chen

Brian K Albrecht

Daniel La

Michael D Bartberger

Lewis D Pennington

Randall W Hungate

Stuart C Chaffee

Ryan Brown

Qingyian Liu

Albert Kudzovi Amegadzie

Michael E Bozik

Kaustav Biswas

Xiaoyang Xia

Kai Zhang

Steven Armen Boyd

Kevin Chao Yang

Chester Chenguang Yuan

Aiwen Li

Vijay Keshav Gore

Rana Nomak

Denise Lyn Andersen

Nobuko Nishimura

Christopher Harold Fotsch

Vu Van Ma

Nianhe Han

Thomas Dineen

Derin C D'amico

David Joseph St Jean, Jr

Benny C Askew, Jr

Babak Riahi

Dean Hickman

Christopher Michael Tegley

Andrew Stewart Tasker

Ben C Askew

Daniel Elbaum

Robert D Groneberg

Julie Germain

Jiawang Zhu

Kelvin C Sham

Nick A Paras

Gregory J Habgood

Mark Hadden

Andras Toro

Jeffrey A Adams

Steve Fong Poon

Kate Ashton

James Zhan

Timothy Powers

Tanya Peterkin

Youngboo Kim

Jennifer N Chau

Charles Raymond Heap

Matthew Walker

Shuang Liu

Hélène Decornez

Hitchcock Stephen

Wenge Cui

Dan Horne

Matthew K Kaller

Nobuku Nishimura

Chuang Liu

James Brown

Albert Amagadzie

Optionally substituted benzoimidazol-1,2-yl amides, such as compounds of Formula 1 or Formula 2, can be used to treat disorders associated with a Kv7 potassium channel activator. Compositions, medicaments, and dosage forms related to the treatment are also disclosed herein.

Benzoimidazol benzomidazol-1,2-yl amides as Kv7 channel activators

Provided herein are optionally substituted benzoimidazol-1,2-yl amides, pharmaceutical compositions comprising a therapeutically effective amount of such compounds and a pharmaceutically acceptable excipient, and methods of treating Kv7 associated diseases, such as, epilepsy, amyotrophic lateral sclerosis, various types of pain, hyperexcitability, a dyskinesia, dystonia, mania and tinnitus with such compounds and pharmaceutical compositions.

KV7 channel activators compositions and methods of use

Benzoimidazol-1,2-yl amides as Kv7 channel activators

Kv7 channel activators compositions and methods of use

Compounds represented by formula 1 can be potent and/or partially selective for the Kv7.2/7.3 heteromultimer. They may be useful in treating disorders related to seizures, pain, neurotransmitter release, etc.

Imidazo[4,5-b]pyridin-2-yl amides as Kv7 channel activators

The present invention provides compounds that are glycine transporter 1 (hereinafter referred to as GlyT-1) inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of GlyT1 such as cognitive disorders associated with Schizophrenia, ADHD (attention deficit hyperactivity disorder), MCI (mild cognitive impairment), and the like. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

Glycine transporter-1 inhibitors

[object Object]

The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I wherein ring A, B, B, B, L, R, R, Rand m of Formula I are defined herein. The invention also includes use of these compounds in pharmaceutical compositions for treatment, prophylactic or therapeutic, of disorders and conditions related to the activity of beta-secretase protein. Such disorders include, for example, Alzheimer's Disease (AD), cognitive deficits, cognitive impairment, schizophrenia and other central nervous system conditions related to and/or caused by the formation and/or deposition of plaque on the brain. The invention also comprises further embodiments of Formula I, intermediates and processes useful for the preparation of compounds of Formula I. 

Amino heteroaryl compounds as beta-secretase modulators and methods of use

Compounds of Formula I are useful as antagonists of TRPM8. Such compounds are useful in treating a number of TRPM8 mediated disorders and conditions and may be used to prepare medicaments and pharmaceutical compositions useful for treating such disorders and conditions. Examples of such disorders include, but are not limited to, migraines and neuropathic pain. Compounds of Formula I have the following structure: where the definitions of the variables are provided herein.

TRPM8 antagonists and their use in treatments

Growing community of inventors

Pittsburgh, PA, United States of America

Scott S Harried